search
Back to results

ELTGOL and Bronchiectasis. Respiratory Therapy (ELTGOLBQ)

Primary Purpose

Respiratory; Complications, Therapy, Bronchiectasis

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Low Expiration Open glottis inferolateral (ELTGOL)
Stretching
Sponsored by
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Respiratory; Complications, Therapy focused on measuring bronchiectasis, respiratory therapy, airway clearance

Eligibility Criteria

18 Years - 95 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All subjects ≥ 18 years old.
  • Diagnosis of bronchiectasis using a high-resolution computed tomography (HRCT) chest scan performed in the last 2 years.
  • Clinically stable disease (defined as no requirement for antibiotics for exacerbation in the 4 weeks preceding study entry.
  • Chronic sputum expectoration >10ml/24h.

Exclusion Criteria:

  • Bronchiectasis secondary to cystic fibrosis.
  • Inability to perform physiotherapy techniques.
  • Inability to attend the following controls.
  • Treatment with mucolytics, DNase or hypertonic saline during the study.
  • Smokers and ex-smokers ≥ 10 pack/year.

Sites / Locations

  • Hospital Universitari Dr. Josep Trueta

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Airway clearance, bronchiectasis

bronchiectasis, stretching

Arm Description

The patient would be selected randomly to one of the two groups (intervention or placebo). And follow up for one year with regular visits with the physician and the respiratory therapist. Each patient will be visited 7 times. At each visit all the variable will be registered. Patient will have also a personal registration diary.

The patient would be selected randomly to one of the two groups (intervention or placebo). And follow up for one year with regular visits with the physician and the respiratory therapist. Each patient will be visited 7 times. At each visit all the variable will be registered. Patient will have also a personal registration diary.

Outcomes

Primary Outcome Measures

To evaluate the efficacy of ELTGOL in stable state patients with bronchiectasis compared to placebo
The primary endpoint for the study is: •Sputum volume during the procedure in the second visit and 24h post treatment which is defined as the volume of mucus expectorated during the physiotherapy procedure and 24h post treatment measured by ml.

Secondary Outcome Measures

Side effects, knowledge
To evaluate the level of knowledge of airway clearance techniques and adherence to them in patients with bronchiectasis. To assess the side effects during the procedure: oxygen desaturation, increased dyspnea and hemoptysis.

Full Information

First Posted
April 13, 2012
Last Updated
November 13, 2017
Sponsor
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Collaborators
Spanish Clinical Research Network - SCReN, Sociedad Española de Neumología y Cirugía Torácica
search

1. Study Identification

Unique Protocol Identification Number
NCT01578681
Brief Title
ELTGOL and Bronchiectasis. Respiratory Therapy
Acronym
ELTGOLBQ
Official Title
Multicenter Randomized Placebo-controlled Trial to Evaluate the Efficacy of the ELTGOL Technique in the Drainage of Secretions in Patients With Bronchiectasis
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
September 2011 (undefined)
Primary Completion Date
September 2011 (Actual)
Study Completion Date
March 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Collaborators
Spanish Clinical Research Network - SCReN, Sociedad Española de Neumología y Cirugía Torácica

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The ELTGOL technique improves mucociliary clearance in adult patients with bronchiectasis. Primary objective: -To evaluate the efficacy of ELTGOL in stable state patients with bronchiectasis compared to placebo. Secondary objectives: To evaluate the level of knowledge of airway clearance techniques and adherence to them in patients with bronchiectasis. To assess the side effects during the procedure: oxygen desaturation, increased dyspnea and hemoptysis.
Detailed Description
The incidence of bronchiectasis has increased in recent years resulting in greater costs, including periods of hospitalisation and the prescription of drugs. The mucociliary clearance mechanism is impaired in these patients, and chest physiotherapy has been recommended for patients with bronchiectasis and chronic productive cough and/or evidence of mucus plugging on HRCT. However, to date, there is insufficient evidence of benefits of chest physiotherapy through randomised controlled trials. Furthermore it rests unclear the most effective technique, the frequency and optimum duration of the RP and the most suitable variables to monitor. A multicenter clinical trial into the efficacy of one chest physiotherapy technique in airway clearance will fill this important "gap" in the scientific evidence.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory; Complications, Therapy, Bronchiectasis
Keywords
bronchiectasis, respiratory therapy, airway clearance

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
44 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Airway clearance, bronchiectasis
Arm Type
Active Comparator
Arm Description
The patient would be selected randomly to one of the two groups (intervention or placebo). And follow up for one year with regular visits with the physician and the respiratory therapist. Each patient will be visited 7 times. At each visit all the variable will be registered. Patient will have also a personal registration diary.
Arm Title
bronchiectasis, stretching
Arm Type
Placebo Comparator
Arm Description
The patient would be selected randomly to one of the two groups (intervention or placebo). And follow up for one year with regular visits with the physician and the respiratory therapist. Each patient will be visited 7 times. At each visit all the variable will be registered. Patient will have also a personal registration diary.
Intervention Type
Procedure
Intervention Name(s)
Low Expiration Open glottis inferolateral (ELTGOL)
Other Intervention Name(s)
airway clearance
Intervention Description
Place the affected lung in infralateral, asks the patient to make an inspiration without being forced to medium volume, and then a slow expiration with the glottis open, down to residual volume. If the therapist is present place the abdominal caudal hand at putting pressure cranial head and hand is placed over the rib cage at a pressure of closing the rib cage. Otherwise, the patient self-administered intertwining arms and abdominal rib at top exerting the same pressure. In case you have two lungs affected the art will take place on one side and then the opposite.
Intervention Type
Procedure
Intervention Name(s)
Stretching
Intervention Description
Patient will be instructed to do muscle stretching of the thorax
Primary Outcome Measure Information:
Title
To evaluate the efficacy of ELTGOL in stable state patients with bronchiectasis compared to placebo
Description
The primary endpoint for the study is: •Sputum volume during the procedure in the second visit and 24h post treatment which is defined as the volume of mucus expectorated during the physiotherapy procedure and 24h post treatment measured by ml.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Side effects, knowledge
Description
To evaluate the level of knowledge of airway clearance techniques and adherence to them in patients with bronchiectasis. To assess the side effects during the procedure: oxygen desaturation, increased dyspnea and hemoptysis.
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
95 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All subjects ≥ 18 years old. Diagnosis of bronchiectasis using a high-resolution computed tomography (HRCT) chest scan performed in the last 2 years. Clinically stable disease (defined as no requirement for antibiotics for exacerbation in the 4 weeks preceding study entry. Chronic sputum expectoration >10ml/24h. Exclusion Criteria: Bronchiectasis secondary to cystic fibrosis. Inability to perform physiotherapy techniques. Inability to attend the following controls. Treatment with mucolytics, DNase or hypertonic saline during the study. Smokers and ex-smokers ≥ 10 pack/year.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Montserrat V Relat, Doctor
Organizational Affiliation
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Universitari Dr. Josep Trueta
City
Girona
ZIP/Postal Code
17007
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
29326318
Citation
Munoz G, de Gracia J, Buxo M, Alvarez A, Vendrell M. Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial. Eur Respir J. 2018 Jan 11;51(1):1701926. doi: 10.1183/13993003.01926-2017. Print 2018 Jan.
Results Reference
derived

Learn more about this trial

ELTGOL and Bronchiectasis. Respiratory Therapy

We'll reach out to this number within 24 hrs